Noncanonical roles of p53 in cancer stemness and their implications in sarcomas

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00077742" target="_blank" >RIV/00159816:_____/22:00077742 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14310/22:00125082

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/abs/pii/S030438352100553X?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S030438352100553X?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.canlet.2021.10.037" target="_blank" >10.1016/j.canlet.2021.10.037</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Noncanonical roles of p53 in cancer stemness and their implications in sarcomas

Popis výsledku v původním jazyce

Impairment of the prominent tumor suppressor p53, well known for its canonical role as the &quot;guardian of the genome&quot;, is found in almost half of human cancers. More recently, p53 has been suggested to be a crucial regulator of stemness, orchestrating the differentiation of embryonal and adult stem cells, suppressing reprogramming into induced pluripotent stem cells, or inhibiting cancer stemness (i.e., cancer stem cells, CSCs), which underlies the development of therapy-resistant tumors. This review addresses these noncanonical roles of p53 and their implications in sarcoma initiation and progression. Indeed, dysregulation of p53 family proteins is a common event in sarcomas and is associated with poor survival. Additionally, emerging studies have demonstrated that loss of wild-type p53 activity hinders the terminal differentiation of mesenchymal stem cells and leads to the development of aggressive sarcomas. This review summarizes recent findings on the roles of aberrant p53 in sarcoma development and stemness and further describes therapeutic approaches to restore normal p53 activity as a promising anti-CSC strategy to treat refractory sarcomas.

Název v anglickém jazyce

Noncanonical roles of p53 in cancer stemness and their implications in sarcomas

Popis výsledku anglicky

Impairment of the prominent tumor suppressor p53, well known for its canonical role as the &quot;guardian of the genome&quot;, is found in almost half of human cancers. More recently, p53 has been suggested to be a crucial regulator of stemness, orchestrating the differentiation of embryonal and adult stem cells, suppressing reprogramming into induced pluripotent stem cells, or inhibiting cancer stemness (i.e., cancer stem cells, CSCs), which underlies the development of therapy-resistant tumors. This review addresses these noncanonical roles of p53 and their implications in sarcoma initiation and progression. Indeed, dysregulation of p53 family proteins is a common event in sarcomas and is associated with poor survival. Additionally, emerging studies have demonstrated that loss of wild-type p53 activity hinders the terminal differentiation of mesenchymal stem cells and leads to the development of aggressive sarcomas. This review summarizes recent findings on the roles of aberrant p53 in sarcoma development and stemness and further describes therapeutic approaches to restore normal p53 activity as a promising anti-CSC strategy to treat refractory sarcomas.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer letters

ISSN

0304-3835

e-ISSN

1872-7980

Svazek periodika

525

Číslo periodika v rámci svazku

January

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

15

Strana od-do

131-145

Kód UT WoS článku

000720470900007

EID výsledku v databázi Scopus

—